First Manhattan CO. LLC. Has $18.89 Million Stake in Boston Scientific Corporation $BSX

Key Points

• First Manhattan Co. LLC reduced its stake in Boston Scientific Corporation by 1.3%, selling 2,551 shares, and now holds 187,272 shares worth approximately $18.89 million.
• Boston Scientific's recent quarterly earnings beat estimates, reporting $0.75 EPS against a consensus of $0.72, with a revenue of $5.06 billion, marking a 22.8% year-over-year increase.
• Institutional investors control over 89% of Boston Scientific's stock, with several entities recently making adjustments to their positions, indicating significant interest in the company.

First Manhattan CO. LLC. trimmed its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 1.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 187,272 shares of the medical equipment provider's stock after selling 2,551 shares during the quarter. First Manhattan CO. LLC.'s holdings in Boston Scientific were worth $18,892,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. NS Partners Ltd grew its stake in shares of Boston Scientific by 1.6% during the first quarter. NS Partners Ltd now owns 368,189 shares of the medical equipment provider's stock valued at $37,143,000 after purchasing an additional 5,704 shares during the last quarter. Bank Pictet & Cie Europe AG grew its stake in shares of Boston Scientific by 40.8% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock valued at $6,529,000 after purchasing an additional 21,173 shares during the last quarter. Oppenheimer & Co. Inc. grew its stake in shares of Boston Scientific by 18.8% during the first quarter. Oppenheimer & Co. Inc. now owns 39,523 shares of the medical equipment provider's stock valued at $3,987,000 after purchasing an additional 6,264 shares during the last quarter. Segall Bryant & Hamill LLC bought a new stake in shares of Boston Scientific during the first quarter valued at approximately $8,234,000. Finally, Blue Trust Inc. grew its stake in shares of Boston Scientific by 13.0% during the first quarter. Blue Trust Inc. now owns 5,000 shares of the medical equipment provider's stock valued at $504,000 after purchasing an additional 575 shares during the last quarter. 89.07% of the stock is owned by institutional investors.

Insider Activity

In other Boston Scientific news, Director Yoshiaki Fujimori sold 2,901 shares of the stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the sale, the director directly owned 2,081 shares in the company, valued at approximately $222,646.19. This trade represents a 58.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the sale, the executive vice president owned 23,600 shares in the company, valued at approximately $2,469,268. This trade represents a 42.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 174,214 shares of company stock valued at $18,397,457. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Trading Down 0.1%

BSX traded down $0.15 during mid-day trading on Friday, hitting $107.14. The stock had a trading volume of 4,062,436 shares, compared to its average volume of 5,787,252. The stock's fifty day simple moving average is $104.77 and its 200-day simple moving average is $102.20. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The firm has a market capitalization of $158.76 billion, a price-to-earnings ratio of 63.78, a price-to-earnings-growth ratio of 2.58 and a beta of 0.65. Boston Scientific Corporation has a 1-year low of $80.64 and a 1-year high of $108.94.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. The company had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business's revenue for the quarter was up 22.8% compared to the same quarter last year. During the same period last year, the business posted $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on BSX. Jefferies Financial Group reissued a "hold" rating on shares of Boston Scientific in a research note on Monday, July 21st. Barclays increased their price target on shares of Boston Scientific from $125.00 to $133.00 and gave the company an "overweight" rating in a research note on Thursday, July 24th. Raymond James Financial increased their price objective on shares of Boston Scientific from $121.00 to $124.00 and gave the company a "strong-buy" rating in a report on Thursday, July 24th. Robert W. Baird increased their price objective on shares of Boston Scientific from $117.00 to $123.00 and gave the company an "outperform" rating in a report on Thursday, July 24th. Finally, Wells Fargo & Company increased their price objective on shares of Boston Scientific from $118.00 to $124.00 and gave the company an "overweight" rating in a report on Thursday, July 24th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $117.50.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.